Clinical trials: Patients With Resistant Depressive Disorders
Depression Disorders
Comparing the Effects of Aerobic & Resistance Exercises and Vitamins D & E on Oxidative Stress & Inflammatory Markers Among Patients with Depression
Depression has been ranked as the fourth leading contributor to disability globally. As per data provided by the World Health Organization (WHO), depression affects approximately 3.8% of the global population, constituting…
- Trial name
- TNF; IL-6 (NCT06775548)
- Testing
- Aerobic Exercises + Vitamin E, Resistance Exercises + Vitamin E, Aerobic Exercises + Vitamin D
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Ziauddin University
Major Depressive Disorder (MDD)
tVNS, Motivation, and Insulin Sensitivity
Disturbances in energy metabolism significantly increase the risk of developing major depressive disorder (MDD), especially in individuals with type 2 diabetes.
- Trial name
- NCT07198100
- Testing
- Transcutaneous non-invasive vagus nerve stimulation (tVNS), Oral glucose tolerance test (oGTT)
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Depressive Disorder, Depression
The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity
The trial will be a four-arm, parallel group, prospective, randomized, double-blind, controlled design that will include 200 participants and will last 20 weeks.
- Conditions
- Depressive Disorder, Depression, Anxiety, Stress
- Trial name
- PRO-DEMET (NCT04756544)
- Testing
- Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Lodz
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Treatment Resistant Depression
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the…
- Trial name
- NCT04519957
- Where
- 8 sites in United States, Czechia and 3 more
- Volunteers
- 66 people
- Sponsor
- COMPASS Pathways
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Major Depressive Disorder
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
The purpose of this study is to assess the efficacy of a Deep Shaped-Field repetitive transcranial magnetic stimulation (DSF-rTMS) system in the treatment of depression.
- Trial name
- NCT01431001
- Testing
- Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
- Where
- 4 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Cervel Neurotech, Inc.
Depressive Disorder, Major
Ketamine Infusions for Major Depression Disorder
Ketamine has been safely used for induction and maintenance of anesthesia for decades and more recently has been used for chronic pain.
- Trial name
- Ketamie (NCT02219867)
- Testing
- Ketamine
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Sheba Medical Center
Major Depressive Disorder
Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)
An open label study to assess the safety, tolerability, and effects of intranasal Ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT04352621
- Testing
- intranasal ketamine, rTMS treatment
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder
Assessing psychiatric and physiological co-morbidity in TRD and non-TRD patients
- Trial name
- NCT00229398
- Sponsor
- Sheba Medical Center
Depression, Bipolar Disorder
Insulin Resistance in Patients With Major Depression
The purpose of this study is to study the relationship between insulin and glucose action and neuropsychological functioning (memory, attention, general thinking abilities) in persons with depression.
- Conditions
- Depression, Bipolar Disorder, Mood Disorders, Insulin Resistance
- Trial name
- NCT01106313
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Stanford University
Treatment Resistant Depression
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF).
- Trial name
- PEMFII (NCT01353092)
- Testing
- Re5 Pulsating ElectroMagnetic Fields, Re5 Pulsating ElectroMagnetic Fields (PEMF)
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hillerod Hospital, Denmark
Major Depressive Disorders
The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMSEYE (NCT06615804)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depressive Disorder, Major
Peripheral Immunomarker Validation in Treatment-resistant Depression
This is a study to characterise the role of inflammatory processes in depression. There is compelling evidence that inflammation is often associated with, and can cause, depression.
- Trial name
- BIODEP (NCT02752178)
- Testing
- MA, DEP
- Where
- 5 sites in United Kingdom
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Depression
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression.
- Trial name
- NCT01128452
- Testing
- EVT 101
- Where
- 14 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Episode, Electroconvulsive Therapy
Electroconvulsive Treatment Followed by Cognitive Control Training
Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high.
- Conditions
- Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation
- Trial name
- ECT-CCT (NCT04383509)
- Testing
- Cognitive Control Training, Active Control
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Ghent
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)